1229 / 1851
DAHANCA19: RT/CRT ± EGFR-I
619
randomized patients
310 patients
zalutumumab
70 ART+ Zalu
21 HF-ART
210 C-ART+Zalu
301 patients in
final analysis
309 patients
control
74 ART
21 HF-ART
212 C-ART
307 patients in
final analysis
2 not eligible:
1 regret participation
1 distant disease
63 locoreg. failures
42 dead of disease
9 not eligible:
8 regret participation
1 died before start
71 locoreg. failures
48 dead of disease
Eriksen 2015